Counterweight Ventures LLC Purchases 79 Shares of Amgen Inc. (NASDAQ:AMGN)

Counterweight Ventures LLC raised its position in Amgen Inc. (NASDAQ:AMGN) by 1.1% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 7,409 shares of the medical research company’s stock after acquiring an additional 79 shares during the quarter. Amgen makes up 1.7% of Counterweight Ventures LLC’s portfolio, making the stock its 25th biggest holding. Counterweight Ventures LLC’s holdings in Amgen were worth $2,387,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Capital Performance Advisors LLP purchased a new stake in shares of Amgen in the 3rd quarter worth $25,000. Hershey Financial Advisers LLC bought a new stake in Amgen during the second quarter valued at about $30,000. nVerses Capital LLC purchased a new stake in Amgen in the second quarter worth about $31,000. Bbjs Financial Advisors LLC bought a new position in shares of Amgen in the second quarter worth about $33,000. Finally, Matrix Trust Co purchased a new position in shares of Amgen during the 3rd quarter valued at about $36,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Trading Down 0.8 %

Shares of AMGN stock opened at $276.40 on Tuesday. The company has a market cap of $148.57 billion, a PE ratio of 35.69, a price-to-earnings-growth ratio of 2.53 and a beta of 0.60. Amgen Inc. has a 1 year low of $260.52 and a 1 year high of $346.85. The stock’s 50 day simple moving average is $319.90 and its two-hundred day simple moving average is $318.65. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, beating the consensus estimate of $5.11 by $0.47. The company had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. Amgen’s quarterly revenue was up 23.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $4.96 EPS. Research analysts predict that Amgen Inc. will post 19.51 earnings per share for the current year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Investors of record on Monday, November 18th will be paid a dividend of $2.25 per share. The ex-dividend date is Monday, November 18th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.26%. Amgen’s dividend payout ratio is presently 115.24%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on AMGN shares. TD Cowen increased their target price on shares of Amgen from $381.00 to $383.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Wolfe Research started coverage on Amgen in a research note on Friday. They issued a “peer perform” rating for the company. Barclays upped their price objective on Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a research note on Monday, October 7th. Citigroup initiated coverage on Amgen in a research note on Thursday, November 14th. They set a “neutral” rating and a $335.00 target price on the stock. Finally, Sanford C. Bernstein initiated coverage on Amgen in a research note on Thursday, October 17th. They issued an “outperform” rating and a $380.00 price target for the company. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $333.57.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.